Review

Factors reported to influence fear of recurrence in cancer patients: a systematic review

Jade V. Crist¹ and Elizabeth A. Grunfeld²* ¹Department of Psychology, King's College London, London, UK ²School of Psychology, University of Birmingham, Birmingham, UK

Abstract

*Correspondence to: School of Psychology, University of Birmingham, Birmingham, UK B15 2TT. E-mail: e.a.grunfeld@bham.ac.uk

Objective: Fear of cancer recurrence (FCR) is a significant psychological problem for cancer survivors. Some survivors experience FCR, which is both persistent and highly distressing. The aim of this systematic review was to identify the key factors associated with fear of recurrence among cancer patients. *Methods:* A comprehensive literature search using keywords was performed with three databases,

followed by an organic search to identify additional relevant articles. Included studies had a quantitative methodology presenting empirical findings focussed on adult cancer patients. A methodological quality assessment was performed for each study, and the strength of evidence was defined by the consistency of results.

Results: Forty-three studies met the inclusion criteria and are presented in this review. The most consistent predictor of elevated FCR was younger age. There was strong evidence for an association between physical symptoms and fear of cancer recurrence. Additional factors moderately associated with increased FCR included treatment type, low optimism, family stressors and fewer significant others. Inconsistent evidence was found for socio-demographic factors.

Received: 14 November 2011 Revised: 25 April 2012 Accepted: 28 April 2012 *Conclusions:* Fear of cancer recurrence is a complex issue influenced by a multitude of factors, including demographic, clinical and psychological factors. However, some studies have reported contradictory evidence, and FCR has been measured using a range of scales, which can hamper comparison across studies. Further research is needed to clarify inconsistencies in the current published research. Copyright © 2012 John Wiley & Sons, Ltd.

Introduction

Advances in the early detection and treatment of cancer have resulted in improved survival rates and an increasing cohort of cancer survivors [1]. Most patients do well following treatment; however, some cancer survivors experience negative emotional outcomes [2]. Anxiety and depression are more common among cancer patients than among the general population with prevalence rates of up to 65% reported [3]. A significant emotional difficulty facing cancer survivors is fear regarding disease recurrence or spread [4]. This is termed fear of cancer recurrence (FCR) [5] and is defined as the fear or worry that cancer will return, progress or metastasise [5,6]. FCR is prevalent with estimates of between 22% and 99% of cancer survivors experiencing FCR [5] and is considered one of the most distressing consequences of cancer [5]. FCR can be long term and may predict poorer quality-of-life outcomes up to 6 years post-diagnosis [7].

A diagnosis of cancer, regardless of the patient's gender or age, brings psychological sequelae, including feelings of vulnerability, a sense of loss and concern for the future [7,8]. Therefore, FCR can be considered a normal and rational response to the threat of recurrence following cancer. However, in some cases, FCR may perpetuate dysfunctional behaviours including avoidance behaviour, hypervigilance for symptoms of recurrence [7] and an inability to plan for the future [9]. In extreme cases, FCR has been associated with the development of anxiety disorders, post-traumatic stress symptoms and depression [5,10–12]. Therefore, identifying patients who are at greater risk of experiencing FCR may improve patient management and inform interventions to reduce FCR. This review aimed to identify factors associated with FCR in cancer survivors.

Method

Three methods were used to identify relevant studies: a keyword search, a backward search and a forwards (citation) search (Figure 1). Literature searches were performed using three electronic databases: Medline (1948–August 2011), PsychINFO (1806–August 2011) and EMBASE (1980–August 2011). The search terms were cancer, cancer patients, oncology, cancer survivors, fear of progression, fear of recurrence, fear* about recurrence, concern* about recurrence. Terms relating to cancer were then combined using OR, as were terms relating to FCR. A further search was performed using the AND function. Duplicates were excluded. A backwards organic search was then performed, which involved hand searching the reference lists of included articles. A forwards (citation) search was then conducted.

Inclusion criteria were as follows: (i) adult cancer patients with any tumour type; (ii) any stage of disease; (iii) being written in English; (iv) quantitative methodology; (v) presentation of empirical findings (i.e. not a review); and (vi) report of data on factors associated with FCR. Studies were excluded if they were published as a conference abstract or a case study. For each study, the following information was obtained: author,




Figure 1. Overview of search strategy

year of publication and demographic information (sample size, age, ethnicity, cancer type, measure of FCR, main findings).

Methodological quality assessment

Each article underwent quality assessment from a checklist of 11 items adapted from an established quality assessment tool [13]. This process was undertaken independently by two researchers, a comparison was made and only minor differences emerged, which were resolved through consensus. The broad nature of the quality assessment allowed a range of methodologies to be assessed. Studies were scored depending on how fully they met each criterion (Table 1): 2-fully meeting the criterion; 1—partially meeting criteria; 0—not meeting the criteria. If a criterion was not applicable, then it was excluded from the score calculation. A total sum score was calculated by summing the number of 'yes' responses then multiplying this by 2 and adding this to the number of 'partials'. The total possible sum was calculated as 22 minus 2 times the number of 'n/a'. Finally, a summary score was calculated (total sum/total possible sum), reflecting the overall methodological quality. Studies were categorised as high quality (score of 17 or above), moderate quality (11 to 16) or low quality (10 or less).

Overall assessment

The information gathered was synthesised into four evidence levels: (i) *strong evidence*: consistent findings of an association in the same direction in at least three studies; (ii) *moderate evidence*: at least two studies reported a significant association in the same direction with one or none in the opposing direction; (iii) *inconsistent evidence*: inconsistent findings whereby no clear directionality in the findings was apparent ; (iv) *weak evidence*: only one study available with supporting evidence or studies consistently identified no association.

Results

The search strategy resulted in 420 bibliographic records, reduced to 257 articles following the exclusion of duplicates and to 36 following application of the inclusion criteria. Backwards organic searching identified a further seven articles. The forwards (citation) search did not identify further relevant articles. Forty-three studies were included in the review. The majority of studies were classified as high quality (Table 1), 11 as moderate quality and none as poor quality. Twenty-two studies focussed on breast cancer, five on prostate and testicular cancers, five on head and neck cancer, one on gynaecological cancers, one on renal cell carcinoma and one on early Barrett's neoplasia. In addition, six studies covered mixed cancer types.

Eleven studies utilised a longitudinal design with follow-up periods ranging from 12 weeks to 18 months and between two and four data collection points. Retention rates between initial and final data collection ranged from 73% to 90%. Eight studies reported that FCR changed minimally over the periods examined [9,14,16,24,55,31,57]. However, three studies reported that FCR decreased between the first two time points measured [21,36,47].

Demographic factors

Younger *age* was consistently associated (in 14 studies) with greater FCR. Older patients reported less fear in breast [6,12,14–16,22–27,47], endometrial [24], orofacial [17], gynaecological [28], testicular [29] and mixed cancer types [56]. In contrast, two studies did not find a significant association between age and FCR [7,18]. However, age remains an important predictor of recurrence worry in multivariate models [14].

Contradictory findings were reported for *gender*, *ethnicity* and *educational status*. Llewellyn and colleagues [7] did not identify any noteworthy relationship between gender and FCR. Simard and Savard [56] found that women reported greater FCR than men although this finding did not hold once cancer type was controlled for. In addition, only one study reported that medium educational level was associated with greater FCR [14].

No clear association between ethnicity and FCR emerged [7]. Two studies reported that African-American survivors were less fearful than Caucasian survivors [26,32]. Moreover, Janz and colleagues [26]

Motoand/dotand/dotand/dotand/dotand/dotand/dotand/dot $(roose a)(l)(M)$ $(roose a)(l)(M)$ $(roose a)(l)(M)$ $(roos a)(l)(M)$ <								
(N) Consertant (Intert) (Not state) (Not	Study	Study design	cancer type(s)	Time since diagnosis	Measures of FCR	Associated with greater FCR		rating
31 6T 41 beak 11 menth potatogy for of heurose Cote(1/3) for a feature contract way constants constant way constant constant way constant	Northouse et al. [18], USA	Cross-sectional	30, breast		Fear of Recurrence Questionnaire	Fewer significant others	r = -0.39*	poM
with the section Constantion Cathodic constants State constants Cathodic constants State constants Cathodic constants State constants Stat	de Haes and Welvaart [23], Netherlands	RCT	41, breast	11 months post-surgery	Fear of Recurrence Checklist [58]	Fewer others understanding concerns Younger age	r= -0.40* r= -0.34*	poM
events Classical State Transitiones and productiones and productines and productiones and productiones and productines	Bartelink <i>et al.</i> [44]. Netherlands	Cross-sectional	172. breast	Not stated	Single item	Mastectomy versus BCT	29% vs 13%*	Mod
	de Haes et al. [41]. Netherlands	RCT	34. breast	II months post-surgery	Based on framework by Meverowitz [58]			ρομ
Prospective S. breakt Nutritional formity portworking Propriodic for stated Sectional formity for stated Sectional	Lasry and Margolese [39], Canada	RCT	123, breast	3.5 years post-surgery	Fear of Recurrence Index	Multiple surgeries	8.2 vs 6.0**	Mod
	Kemeny et al. [45], USA	Prospective	52, breast	18 months post-surgery	Psychosocial reactions to surgery [59]	Mastectomy versus BCT	2.0 vs 1.3*	Mod
n Consistional Longutinal Not State Not Ear of rearrence Scale [61] Not Scale Sole Not Ear of rearrence [53] Not Ear of Rearrence Quetionnowe [13] Not Ear of Rearrence Scale [13] Not Adviser of Rearrence Scale [13] <	Lasry et al. [40], Canada	RCT	123, breast	Not stated	Fear of Recurrence Index [39]	Chemotherapy	Full results missing*	Mod
North Induction Congregation Fair of neurone Size [60] Congregation Induction Remoth Elouon 202, semecological 640, beas; Not status Ear of neurone [29] Us of psycholicial peaps; In result in a status Remoth Elouon 202, semecological 64, pairs Fair of fearmone Size [60] Us of psycholicial peaps; In result in a status Attain 202, semecological 64, pairs Ear of fearmone Size [60] Vonger age Ear of resumme [18] Vonger age Ear of semente [20] Ear of resumme [18] Vonger age Ear of semente [20] Ear of resumme [18] Vonger age Ear of semente [20] Ear of resumme [18] Vonger age Ear of semente [20] Ear of resumme [18] Vonger age Ear of semente [20] Ear of resumme [20] Ear of	Noguchi et al. [42], Japan	Cross-sectional	90, breast	Not stated	Single item	NA NA		Mod
A Orophonion (montholinewic) 40. heart for montholinewic) 40. heart for montholinewic)	Curran <i>et al.</i> [22], UK	RCT	278, breast	Not stated	Fear of Recurrence Scale [60]	Younger age	Full results missing**	High
a Consertional Construction Construction Construction Manuage (Bumstein <i>et al.</i> [57], USA	Longitudinal	480, breast	Newly diagnosed	Fear of recurrence [38]	Use of psychological therapies	8.17 vs 7.51**	High
a Congregation 20.2 genet colgation 0-6 years Functional Ling display 20.2 genet colgation Nam gad ys 54* (12-month follow-up) 7.0 heatt Nam gad ys 54* Nam gad ys 54* Nam gad ys 54* Africa 12.4 month follow-up) 7.0 heatt Nat stated For of Reumence Outstionnaire (18) Younge age = -0.35** Africa 27.4 heatt 13.6 heatt 13.6 heatt 13.6 heatt Single term Nam Nam gad ys 55.3* Vindica 37. orofficial 13.7 orofficial C1 years Single term Nam matter term 53.7 erofficial 13.9 × 55.3* Nin Prospective and 37. orofficial Nam Nam matter term 53.7 erofficial 13.9 × 55.3* Nin Prospective and 37. orofficial Nam Nam matter term 53.7 erofficial 13.9 × 55.3* Nin Retropective and 37. orofficial Nam Nam matter term 53.8 × 55.3* Nin Retropective and 10.0 orofficial Nam Nam 10.9 × 55.3* Nin Retropective and		(9-month follow-up)						
Longludini Zo, breat Not stated Fair of Reumence Questionnaire [16] Consign and anticas oriental) r=-0.33** Africa RCT 136, breat Not stated 5ngle item Non r=-0.33** Africa RCT 136, breat Not stated 5ngle item Non r=-0.33** Africa RCT 136, breat 42, years 5ngle item Non r=-0.33** Africa S19, prostate 274, breat 519, prostate Non r=-0.33** Arronth follow-up 87, created carciona 80, ordinal Non ordinal 199, or 53.9* Anothic 198, prestate Not stated Fan of Recurrence Scale [62] Monethy of life r=-0.33** 100, ordinal 199, prostate Not stated Fan of Recurrence Scale [62] Monethy of life r=-0.33** 101 69, breast 3 years Consign and life or carcion r=-0.33** 103, ordinal life 69, breast Fan of Recurrence Scale [62] Monethy of life r=-0.33** 101 101, oroint fallow-up 101, erea	Leake <i>et al.</i> [28], Australia	Cross-sectional	202, gynaecological	0-6 years	Functional Living Index [61]	Younger age	Mean age 49 vs 54*	High
(12-month follow-up) r=-033*** RCT 136, breast Nux stated Single term Nux r=-033*** Prospective and solution 136, breast 136, breast Nux r=-033*** Prospective and solution 87, ordical Nux r=-033*** r=-033*** Description 81, ordical Nux r=-033*** r=-033*** Description 81, ordical Nux r=-033*** r=-033*** Description 81, ordical Nux r=-033*** r=-033*** Description 19, ordical Nux r=-033*** r=-033*** Description 10, ordical Nux r=-033*** r=-033*** Description 10, ordical Nux r=-033*** r=-033*** Description 10, ordical Nux r=-033*** r=-033*** De	Stanton et al. [16], USA	Longitudinal	70, breast	Not stated	Fear of Recurrence Questionnaire [18]	Younger age	$r = -0.36^{**}$	High
RCT 136, breast Not stated Single term PONS sjour r=0.053** Propetcine 274, breast 42 yans Single term NA		(I 2-month follow-up)				Coping (avoidance oriented)	r=-0.33**	
RCT 13, breat; Not stated Single term Nork syot $r=-0.33^{++}$ Propective 274, breat; 42 years Single term Overse mattectumy 63 years' Prospective and cross exclored 87, oroticial -2 years post-treatment Single term Yourge rage $< \frac{59}{2}$ years' Prospective and cross exclored 87, oroticial 0.0 , oroticial 0.0 , oroticial 0.9 , prestatement Single term 0.9 , oroticial 0.9 , oroticial 0.9 , oroticial 0.9 , prestatement 0.9 , p						POMS distress	r=0.60**	
RCT13, breat:Not statedSingle termNA $-$ Prospective274, breat:4.2 yearsSingle termComperative6.3 yr. 55.3*Prospective and87, orotical(2.1 years)Comperative6.3 yr. 55.3*Prospective and87, orotical(2.1 years)Single termComperative7.3 yr. 55.3*Prospective and87, orotical(1.2 workical(1.2 workical(1.2 workical(1.2 workicalProspective and87, orotical(1.2 workicalNot statedFear of Recurrence Scale (6.2)Mandatory nephron-spaning surger(2.9 sea*Prospective169, breast37, reval cell carcinomaNot statedFear of Recurrence Scale (6.2)Mandatory nephron-spaning surger(3.9 s. 5.3.*Prospective169, breast37, reval cell carcinomaNot statedFear of Recurrence Scale (6.2)Mandatory nephron-spaning surger(3.9 s. 5.3.*Longludinal69, breastNot statedNot statedNot stateNot state(3.9 s. 5.3.*Longludinal69, breastNot statedNot statedNot state(3.9 seas(3.9 seasLongludinal61, breastNot statedNot stateNot state(3.9 seas(3.9 seasLongludinal87, headmeckNot statedNot stateNot state(3.9 seas(3.9 seasLongludinal87, headmeckNot statedNot stateNot state(3.9 seas(3.9 seasLongludinal87, headmeckNot statedNot stateNot state(3.9						POMS vigour	r = -0.53 * *	
Prospective27, least4.2 yearsSingle termBCT versus matchomy6.39 vs.53.* (3.9 vs.53.*Prospective and cross-sectional87, ondical<2 years post-treatment	de Haes <i>et al.</i> [43], UK, Netherlands, Greece, S. Africa	RCT	136, breast	Not stated	Single item	NA	I	High
Propertie and consistentional (00. orditical (24-month follow-up)8, orditical (00. orditical (24-month follow-up)Comper age (24-month follow-up)Conservational (24-month follow-up)Conservati	Härtl et al. [25], Germany	Prospective	274, breast	4.2 years	Single item	BCT versus mastectomy	63.9 vs 55.3*	High
Prospective and constactional87, orofacial $< 2 \text{ years post-treatment}$ Single term AnotecyCongret age Anotecy $?^2 = 331^{\circ \circ}$ Longulutional519, prostateNot statedFear of Recurrence Scale [62]Poorer quality of life $\beta = -0.23^{\circ \circ}$ Retrospective37, renal cell carcinomaNot statedFear of Recurrence Scale [62]Poorer quality of life $\beta = -0.23^{\circ \circ}$ Retrospective169, breastNot statedFear of Recurrence Scale [62]Prandatory nephron-sparing surgery $\beta = -0.23^{\circ \circ}$ Cross-sectional169, breast3 yearsConcerns about Recurrence Scale [62]Prandatory nephron-sparing surgery $\beta = -0.23^{\circ \circ}$ Longulutinal69, breast3 yearsConcerns about Recurrence Scale [62]Nandatory nephron-sparing surgery $\beta = -0.23^{\circ \circ}$ Longulutinal69, breastNot statedFear of Recurrence Scale [62]Nandatory nephron-sparing surgery $\beta = -0.23^{\circ \circ}$ Longulutinal24, breastNot statedNot statedNonger age $\beta = -0.23^{\circ \circ}$ Longulutinal87, head/neckNot statedNony of Cancer Scale [52]New symptoms $\beta = -0.23^{\circ \circ}$ Longulutinal87, head/neckNot statedNony of Cancer Scale [52]New symptoms $\beta = -0.23^{\circ \circ}$ Longulutinal87, head/neckNet statedNon statedNon stated 47% Longulutinal87, head/neckNot statedNon statedNon stated 7% Longulutinal87, head/neckNot statedNon statedNon stat						Younger age	<59 years*	
	Humphris et al. [17], UK	Prospective and	87, orofacial	<2 years post-treatment	Single item	Younger age	$\chi^2 = 9.31*$	High
Longtudinal (24-month follow-up)519, prostateNot statedFear of Recurrence Scale [62]Poorer quality of life $\beta = -0.23^{*}$ $(24-month follow-up)357, renal cell carcinomaNot statedFear of Recurrence Scale [62]Mandatory nephron-sparing surgery19, 10, (17.85 to 20.54)^{*}Cross-sectional169, breast3 yearsConcerns about Recurrence Scale [62]Mandatory nephron-sparing surgery?^{1} = 0.833.0^{**}Longtudinal69, breastNot statedFear of Recurrence Scale [62]BCT versus mastectomyMean difference = 9^{**}Longtudinal69, breastNot statedFear of Recurrence Scale [62]BCT versus mastectomyPear of fear of Recurrence = 9^{**}Longtudinal69, breastNot statedFear of Recurrence Scale [62]Breast approventionsProvende Jog 826Uomonth follow-up)244, breast68 yearsTriggers of uncertaintyHearing about another's carcerReported by 825Uomonth follow-up)87, head/incleNot statedNon yontomsB83Annual (Pack-up)Unorth follow-up)87, head/incleNot statedFear of Recurrence Questionnaire [18]Low sense of coherenceF= 2.89^{**}Longtudinal87, head/incleNot statedFear of Recurrence Questionnaire [18]Low sense of coherenceF= 6.13^{**}Longtudinal10,-month follow-up)36, heamatobgicalNot statedFear of Recurrence Questionnaire [18]Low sense of coherenceF= 6.13^{**}Longtudinal10,-month14, breastNot statedFear of Recur$		cross-sectional	100, orofacial			Anxiety	$\chi^2 = 7.57^{**}$	
(x+mount follow-up) Mandatory nephron-sparing surgery [19] (G1735 to 2034)* Retrospective 357, renal cell carcinona Not stated Fear of Recurrence Scale [62] heast [19] (G1735 to 2034)* Cross-sectional 169, breast 3 years Concerns about Recurrence Scale BCT versus mastectomy Pean difference = 9*** Longitudinal 69, breast Not stated Fear of Recurrence Scale BCT versus mastectomy Pean difference = 9*** Longitudinal 69, breast Not stated Fear of Recurrence Scale BCT versus mastectomy Pean difference = 9*** Longitudinal (+-month follow-up) 244, breast 6.8 years Triggers of uncertainty Imeas perceptions (timeline) F = 5.07** Longitudinal (10-month follow-up) 244, breast 6.8 years Triggers of uncertainty New symptoms B8% Longitudinal 87, head/neck Not stated Not stated Non of Cancer Scale [62] New symptoms B8% Longitudinal 87, head/neck Not stated Not stated Non of Cancer Scale [62] New symptoms B8% Longitudina	Mehta et al. [19], USA	Longitudinal	519, prostate	Not stated	Fear of Recurrence Scale [62]	Poorer quality of life	$\beta = -0.23^{*}$	РоМ
Retrospective357, renal cell carcinomaNot statedFear of Recurrence Scale [62]Mandatoly nephron-sparing surgery19, 19, (CI 17.85 to 20.3-)*Cross-sectional169, breast3 yearsConcerns about Recurrence ScaleLarger tumour size2 = 0.063.0**Longitudinal69, breastNot statedFear of Recurrence Scale [62]Stage 2 vs 1 $F = 5.07**$ (4-month follow-up)244, breast6.8 yearsTriggers of uncertaintyHeaning about another's cancerReported by 82%(0-month follow-up)244, breast6.8 yearsTriggers of uncertaintyHeaning about another's cancerReported by 82%(10-month follow-up)3, head/neckNot statedWonry of Cancer Scale [59]Stage 2 vs 1 $F = 5.07**$ Longitudinal87, head/neckNot statedWonry of Cancer Scale [59]Smokers/relipsed versus quitters $F = 5.07**$ Longitudinal87, head/neckNot statedWonry of Cancer Scale [59]Smokers/relipsed versus quitters $F = 5.07**$ Longitudinal87, head/neckNot statedWonry of Cancer Scale [59]Longitudinal 7.8 Cross-sectional87, head/neckNot statedNort stated $F = 5.07**$ Scase sectional87, head/neckNot stated $V = 0.54**$ Cross-sectional87, head/neckNot stated $F = 0.69**$ Cross-sectional87, head/neckNot stated $F = 0.69**$ Cross-sectional84, breastNot stated $F = 0.69**$ Cross-sectional44, breast $F = 0.69**$ <td></td> <td>(24-month tollow-up)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		(24-month tollow-up)						
Cross-sectional16% heast3 yearsConcens about Recurrence ScaleBCT versus mastectomyMean difference = 9** Nean difference = 9**Longitudinal (4+month follow-up)6% heastNot statedFear of Recurrence Scale [62]Stage 2 vs 1Fean difference = 9** Fear of Recurrence Scale [62]Non statedLongitudinal (10-month follow-up)244, heast6.8 yearsTriggers of uncertaintyHear of Recurrence Scale [62]Stage 2 vs 1Fean difference = 9** Fear of Recurrence Scale [62]Longitudinal (10-month follow-up)87, head/neckNot statedNon vortice faintyNew symptons8% 63%Longitudinal (12-month follow-up)87, head/neckNot statedVorty of Cancer Scale [59]New symptons63% 63%Longitudinal (12-month follow-up)36, heamatologicalNot statedFear of Recurrence Questionnaire [18]Low sense of coherenceF = 2.69** 7%Longitudinal (12-month follow-up)36, heamatologicalNot statedFaar of Recurrence Questionnaire [18]Low sense of coherenceF = 6.15* 7%Longitudinal (12-week follow-up)44, heastNot statedSingle itemr = 0.63** 8mast cancer symptonsr = 0.63** 1= 0.44**	Poulakis et <i>a</i> l. [38], Germany	Retrospective	357, renal cell carcinoma		Fear of Recurrence Scale [62]	Mandatory nephron-sparing surgery Larger tumour size	19.19 (Cl 17.85 to 20.54)* r ² = 0.8530**	High
Longitudinal (4-month follow-up)6,9, breast (4-month follow-up)Not stated (4-month follow-up)Not stated (4-month follow-up)Mean difference = 9** (10-month follow-up)(10-month follow-up) (10-month follow-up)244, breast (10-month follow-up)6.8 years (10-month follow-up)Fear of Recurrence Scale [62]New symptoms New symptomsReported by 82% (10-month follow-up)(10-month follow-up) (10-month follow-up)87, head/neckNort statedNorty of Cancer Scale [59]New symptoms New symptoms83% (10-month follow-up)(10-month follow-up) (10-month follow-up)87, head/neckNort statedNorty of Cancer Scale [59]New symptoms New symptoms83% (10-month follow-up)(10-month follow-up) (10-month follow-up)3, heamatologicalNort statedNorty of Cancer Scale [59]Nore strifters of the clup (10-month follow-up) $f=2.89*$ (12-month follow-up)Longitudinal (12-month follow-up)41, breast $f=2.81*$ (12-month follow-up) $f=2.89*$ (12-month follow-up)Longitudinal (12-week follow-up)41, breast $f=2.81*$ (12-week follow-up) $f=2.81*$ (12-week follow-up)Longitudinal (12-week follow-up)41, breast (12-week follow-up) $f=2.81*$ (12-week follow-up) $f=2.81*$ (12-week follow-up)Longitudinal (12-week follow-up)41, breast (12-week follow-up) $f=2.81*$ (12-week follow-up) $f=2.81*$ (12-week follow-up)Longitudinal (12-week follow-up)41, breast (12-week follow-up) $f=2.81*$ (12-week follow-up) $f=2.81*$ (12-week follo	Vickberg [6], USA	Cross-sectional	169, breast	3 years	Concems about Recurrence Scale	BCT versus mastectomy	Mean difference = 9^{**}	High
						Younger age	Mean difference = 9^{**}	
(4-month follow-up) (1-month follow-up) F = 9.69** Longitudinal 244, breast 6.8 years Triggers of uncertainty Hearing about another's cancer Reported by 82% (10-month follow-up) 87, head/neck Not stated Wonry of Cancer Scale [59] New symptoms 88% Longitudinal 87, head/neck Not stated Wonry of Cancer Scale [59] Smokens/relapsed versus quitters 77% Longitudinal 36, haematological Not stated Wonry of Cancer Scale [59] Low sense of coherence 75% Longitudinal 36, haematological Not stated Fear of Recurrence Questionnaire [18] Low sense of coherence F= 6.15* Longitudinal 44, breast Not stated Single item Younger age r= 0.33** Longitudinal 12-week follow-up) Ear of Recurrence Scale [62] Denial coping r= 0.33** Longitudinal 44, breast Not stated Single item Younger age r= 0.34**	Rabin et al. [36], USA	Longitudinal	69, breast	Not stated	Fear of Recurrence Scale [62]	Stage 2 vs	$F = 5.07^{**}$	High
Longitudinal244, breast6.8 yearsTriggers of uncertaintyHearing about another's cancerReported by 82% $(10-month follow-up)$ $(10-month follow-up)$ New symptoms83% $(10-month follow-up)$ 87 , head/neckNot stated 47% Longitudinal 87 , head/neckNot statedWorry of Cancer Scale [59]Smokers/relapsed versus quitters 47% Longitudinal 36 , haematologicalNot statedFear of Recurrence Questionnaire [18]Low sense of coherence $F=2.89^{*}$ Longitudinal 44 , breastNot statedFear of Recurrence Scale [62]Denial coping $r=0.53^{**}$ Longitudinal 44 , breastNot statedSingle itemYounger age $r=0.34^{*}$ Longitudinal 10^{*} , breastNot statedSingle itemYounger age $r=0.34^{*}$		(4-month follow-up)				Illness perceptions (trimeline)	F = 9.69 * *	
(10-month follow-up) New symptoms 88% Nedia Information 87, head/neck Not stated 47% Longitudinal 87, head/neck Not stated 47% Longitudinal 87, head/neck Not stated 47% (12-month follow-up) 56, haematological Not stated 47% Cross-sectional 36, haematological Not stated Fear of Recurrence Questionnaire [18] Even sense of coherence Longitudinal 44, breast Not stated Single item Penial coping r=0.53** Longitudinal 10-week follow-up) Even stated Single item r=0.34*	Gil et al. [31], USA	Longitudinal	244, breast		Triggers of uncertainty	Hearing about another's cancer	Reported by 82%	High
Longitudinal 87, head/neck Not stated Worry of Cancer Scale [59] Media Information 63% Longitudinal 87, head/neck Not stated Worry of Cancer Scale [59] Smokers/relapsed versus quitters 47% (12-month follow-up) 36, haematological Not stated Fear of Recurrence Questionnaire [18] Low sense of coherence F=2.89* Longitudinal 44, breast Not stated Fear of Recurrence Scale [62] Denial coping r=0.53** Longitudinal 10-week follow-up) Periar coping r=0.034* r=0.034*		(10-month follow-up)				New symptoms	88%	
Longitudinal 87, head/neck Not stated Worry of Cancer Scale [59] Annual check-up 47% (12-month follow-up) 36, haematological Not stated Worry of Cancer Scale [59] Smokers/relapsed versus quitters F=2.89* Cross-sectional 36, haematological Not stated Fear of Recurrence Questionnaire [18] Low sense of coherence F=6.15* Longitudinal 44, breast Not stated Single item Younger age r=0.34* (12-week follow-up) Reast cancer symptoms r=0.44**						Media Information	63%	
Longitudinal 87, head/neck Not stated Wonry of Cancer Scale [59] Smokers/relapsed versus quitters F = 2.89* (12-month follow-up) 36, haematological Not stated Fear of Recurrence Questionnaire [18] Low sense of coherence F = 6.15* Cross-sectional 36, haematological Not stated Fear of Recurrence Questionnaire [18] Low sense of coherence F = 6.15* Longitudinal 44, breast Not stated Single item Younger age r = 0.33** (12-week follow-up) Reast cancer symptoms r = 0.34* r = 0.34*						Annual check-up	47%	
Cross-sectional 36, haematological Not stated Fear of Recurrence Questionnaire [18] Low sense of coherence F=6.15* Longtudinal 44, breast Not stated Single item Younger age r=0.33** (12-week follow-up) (12-week follow-up) Perial coping r=0.34*	Humphris and Rogers [55], UK	Longitudinal (12-month follow-up)	87, head/neck	Not stated	Worry of Cancer Scale [59]	Smokers/relapsed versus quitters	F = 2.89*	High
Longitudinal 44, breast Not stated Single item Derial coping r = 0.53** (12-week follow-up) Younger age r = -0.34* Breast cancer symptoms r = 0.44**	Black and White [10], UK	Cross-sectional	36, haematological	Not stated	Fear of Recurrence Questionnaire [18] Fear of Recurrence Scale [62]	Low sense of coherence	F = 6.15*	PoM
Longruennal 1+1, breast Not stated Single item Uenial coping r = 0.33*** (12-week follow-up) Younger age r = 0.34** Breast cancer symptoms r = 0.44**								+
i ourger age Breast cancer symptoms	Wade et αl. [47], Australia	Longitudinal	44, breast	Not stated	Single item	Veniation coping	r= 0.53** r 0.34*	Hgh
		(dn-maini hadan - ti)						
						DICASE CALICAL SYLLIPEOLIES		

Fear of recurrence

Table I. Summary of studies

Table I. Continued							
Study	Study design	Sample size, cancer type(s)	Time since diagnosis	Measures of FCR	Associated with greater FCR		Quality rating
Deimling et al. [32], USA	Cross-sectional	321, breast, colorectal, prostate	10.4 years	Cancer related Health wornies Scale 1631	Race (African-American) Optimism Sumstoms	$\beta = -0.22 **$ $\beta = -0.27 **$ $\beta = 0.20 *$	High
Constanzo et <i>al.</i> [14], USA	Longitudinal (5-month follow-up)	89, breast	Not stated	concerns about Recurrence Scale [6]	Jyripours Younger age Lower education Matertomv	F = 9.90** F = 7.65** F = 6.45*	High
Komblith et al. [24], USA	Longitudinal (12-month follow-un)	252, breast, endometrial	Not stated	Fear of Recurrence Scale [62]	Younger age Breast cancer	F = 26.58** F = 1748*	High
Mellon <i>et al.</i> [30], USA	Secondary analysis	123, breast, colon, uterine, prostate	3.4 years	Fear of Recurrence Questionnaire	Concurrent family stressors Less positive meaning of illness Co-morbidities	r = 0.31** r = -0.43** r = 0.55**	High
Steele et al. [34], UK	Cross-sectional	100, colorectal	Not stated	Single item	Somatic concerns Young children	Г = 0.17* 50% vs 22%* Б.Ш. кост.Не койстоле**	High
Bellizi et al. [21], USA	Longitudinal (12-month follow-up)	730, prostate	Not stated	Fear of Cancer Recurrence Scale [62]	Concern acout results Poorer mental quality of life Reduction in FCR post-treatment	t un results initiating a t = 3.74** Full results missing**	High
Hart et <i>al.</i> [9], USA	Longitudinal (18-month follow-up)	333, prostate	Not stated	Fear of Cancer Recurrence Scale [62]	Less treatment satisfaction Poorer mental quality of life Poorer physical quality of life	r = -0.32 ** r = -0.43 ** r = -0.30 **	High
Llewellyn et al. [7], UK	Prospective	82, head/neck	Newly diagnosed	Single item	Product purportan quanty or me Perceptions of severe consequences Stronger emotional representations Denial coping Positive reframing coping Use of religion coping Planning coping Lower optimism	r = 0.39** r = 0.39** r = 0.38** r = 0.29* r = 0.29* r = 0.40**	Щ. Б
van den Beuken-van Everdingen et <i>al.</i> [12], Netherlands	Prospective	I 36, breast	Not stated	Concems about Recurrence Scale [6]	Greater anxiety Pain Younger age Poorer quality of life Physical functioning Social functioning Role limitations Mental health Vitality	$r = 0.50^{**}$ $\beta = 0.28^{**}$ $\beta = -0.2^{*}$ $r = -0.2^{**}$ $r = -0.24^{**}$ $r = -0.57^{***}$ $r = -0.38^{***}$	Ей Т
Bergman et <i>al.</i> [33], USA Hodges and Humphris [20], UK Mehnert et <i>al.</i> [15], Germany	Prospective Prospective Cross-sectional	476, prostate 101, head/neck 1083, breast	Not stated Newly diagnosed 3.9 years	Memorial Anxiety Scale [64] Worry of Cancer Scale [59] Fear of Progression Questionnaire [65]	General health Unpartnered patients Distress Married/divorced Unemployed Younger age Children Disease progression/ recurrence Chemotherapy Perresived impaiments Depressive coping Active problem-oriented coping	r = -0.27 *** Parameter estimate 5.79* $\beta = 0.22 **$ $\eta = 0.02 **$ r = -0.17 *** d = 0.14 ** $\eta = 0.01 **$ $\eta = 0.02 **$	E I I E I I E

J. V. Crist and E. A. Grunfeld

High	.E B	High	poM	High High Bigh	High
$\beta = 1.80 ** \\ \beta = 0.55 ** \\ \beta = 0.62 ** \\ \beta = 0.69 *** \\ \beta = 0.45 ** \\ r = 0.31 ** \\ r = -0.31 ** \\ r = -0.31 ** \end{cases}$	r = 0.12*** r = 0.10*** r = 0.14** OR 1.51 * * OR 1.24** OR 1.18**	$\begin{array}{l} OK \ 1.04^{**} \\ \beta = -0.16^{*} \\ \beta = 0.14^{*} \\ \beta = 0.61^{**} \\ R = 0.58^{**} \end{array}$	69%* 67%** 35%*	Mean difference = 10^{**} $F = 5.76^{**}$ $r = -0.26^{**}$ OR = 28.6^{*} Full results missing [*]	$\beta = 0.86 ** \\ \beta = -0.34 ** \\ \beta = 0.12 * \\ \beta = 0.48 ** \\ \beta = 0.39 ** \\ \beta = 0.29 ** \end{cases}$
Intrusion coping Avoidance coping Hyperarousal coping Women Younger age	Radiotherapy Surgery Cancer progression Younger age Neuroticism Intrusion	Avoidance Younger age Stage of disease High threat appraisal Porreviewd vulverohitiv	Low mood about cancer Anxious about cancer Pooner quality of life	Oesophagus-preserving treatment Recurrence Dissatisfaction with treatment Intrusive thoughts No prostate cancer	Ethnicity Younger age Employed Pain Fatigue Radiotherapy
Concems about Recurrence Scale [6] Fear of Recurrence Questionnaire [18]	Single item	Modified Cancer Worry Scale [35]	Fear of Recurrence Questionnaire [18]	Worry of Cancer Scale [59] Fear of Progression Questionnaire [4] Fear of Cancer Recurrence Inventory [1]	Worry of Cancer Scale [59]
4.9 years 4.9 years 3 Avaars	4.2 years 11.4 years	6–24 months post-treatment	Not stated	Not stated 14.5 months 3.3– 4.3 years	Not stated
227, breast 246, prostate 49 hros	78, colorectal I 336, testicular	155, breast	123, head and neck (cohort 1) 68, head and neck (cohort 2)	95, Barrett's neoplasia 112, breast, gastrointestinal, lung, other 977, breast 92, lung 727, prostate	188, colorectal 1837, breast
Cross-sectional	Cross-sectional	Cross-sectional	Cross-sectional	Cross-sectional Case-control Cross-sectional	Cross-sectional
Simard and Savard [56], Canada	Skaali et <i>d</i> . [29], Norway	McGinty et al. [27], USA	Rogers et al. [35], UK	Rosmolen et al. [46], Netherlands Cross-sectional Shim et al. [37], South Korea Case-control Simard et al. [5], Canada Cross-sectional	Janz et <i>d</i> . [26], USA

NA, no association; BCT, breast-conserving treatment; POMS, Profile of Mood States; RCT, randomised controlled trial; FCR, fear of cancer recurrence; OR, odds ratio; CI, confidence interval.

Fear of recurrence

also identified higher levels of worry about recurrence among Latina women.

There was a mixed pattern of findings for marital status. Six studies reported that following multivariate analysis marital status was unrelated to FCR [5,7,12,18,26,28]. In comparison, Bergman and colleagues [33] found that men with partners reported less fear of recurrence, and a further study reported that being either married or divorced was associated with greater FCR [15].

Concurrent family stressors were predictive of elevated FCR [30]. Family resources, including family hardiness and social support, were unrelated to FCR although women who had fewer significant others with whom they could discuss concerns reported greater FCR [18]. Mehnert and colleagues [15] found that having children was significantly associated with FCR. In addition, having younger children (under 21) was associated with greater FCR [34].

Cancer and treatment-related factors

None of the studies included in the review found an association between time since diagnosis and severity of self-reported FCR [6,15,30,56]. There were some differences in reports of FCR across cancer types. Prostate cancer patients reported lower FCR than patients with breast, colorectal and lung cancer [5]. However, greater FCR was observed among breast cancer survivors than among endometrial cancer survivors [24].

Five studies reported that cancer stage was not associated with FCR [6,12,18,19,26]. In contrast, two studies [27,36] reported that breast cancer patients with stage I diagnosis reported less FCR than patients with stage II. Moreover, patients with cancer recurrence or progression reported greater FCR in comparison with controls [37].

Mixed evidence emerged for an association between treatment type and FCR. Skaali and colleagues [29] reported that treatment type for prostate and testicular cancer was not a significant predictor. However, five studies reported that chemotherapy was related to greater FCR among breast cancer survivors [14,15,38,39], although this was not upheld in multivariate analyses. In a further multivariate analysis with a breast cancer sample, radiation therapy was predictive of greater worry [26]. Four studies found no relationship between treatment type and FCR [18,28,30,35] among a range of cancer types. However, the relationship between treatment type and FCR was reported to be influenced by treatment satisfaction [9] and symptom control [26].

Mixed evidence emerged for an association between type of surgery and FCR. Eight studies reported no difference between mastectomy and breast-conserving therapy [6,22,23,40–43]. However, two studies [6,25] reported that patients undergoing breast-conserving therapy reported greater FCR than mastectomy patients. Conversely, three studies reported greater FCR among mastectomy patients compared with those receiving breast-conserving therapy [14,44,45]. The discrepancy may partly be explained by the differing methodologies used and by the single treatment centre focus of most studies, whereby there may have been different surgical approaches or information provision. Patients who underwent compulsory nephron-sparing surgery for renal cell carcinoma were significantly more fearful of cancer recurrence than those who underwent radical nephrectomy or elective nephron-sparing surgery [38]. In addition, one study reported that preserving the oesophagus using endoscopic therapy in early Barrett's neoplasia resulted in greater reported FCR [46].

Psychological factors and coping responses

Mixed evidence emerged for the association between psychological factors and FCR. One study identified the association between personality, in particular neuroticism, and FCR [29]. Furthermore, an association was found between low mood or psychological distress (including anxiety and depression) and FCR [7,16,17,20,35], although the directionality of such a relationship was not apparent. Finally, two studies also identified an association between intrusive thoughts and FCR [5,29].

Two studies [7,32] reported that lower optimism was associated with greater FCR, and optimism was the strongest predictor of FCR following treatment (excluding baseline FCR) [7]. The same study identified that illness perceptions, including perceptions of more severe consequences and stronger emotional representations, were associated with FCR. In addition, conceptualising cancer as a chronic illness was associated with greater FCR [36]. Furthermore, greater perceived physical impairments [15] and appraising cancer as having less positive meaning [30] was associated with greater FCR. McGinty and colleagues [27] reported a correlation between risk perceptions of breast cancer (vulnerability and severity) and greater FCR.

Low self-esteem, denial coping and avoidanceorientated coping were predictors of future FCR [16,29,47]. In addition, both depressive coping and active problemoriented coping were associated with greater FCR [15].

Quality-of-life domains were associated with FCR in five of the studies. In four studies, there was an observed association between poorer physical and mental-health-related quality of life and FCR [9,12,19,35]. In one study, there was an association between mental-health-related quality of life only and FCR [21].

Factors triggering FCR

One study reported that hearing of another's diagnosis, exposure to media information or an annual check-up influenced reports of FCR [31]. In addition, experiencing new or ongoing side effects or symptoms (especially pain) was associated with reports of greater FCR [12,26,29,30,32]. Furthermore, Humphris and Rogers [47] identified a weak relationship between FCR and smoking behaviour.

Discussion

This review aimed to identify factors associated with FCR in cancer patients. Strong evidence emerged for a relationship between FCR and younger age, coping responses, poorer quality of life and cues (new symptoms, pain and follow-up appointments). Moderate evidence was found for beliefs (e.g. perceptions of vulnerability)

Fear of recurrence

and demographic factors (ethnicity, having younger children). Finally, inconclusive or weak evidence was found for cancer-related factors (cancer type, stage, treatment type), socio-demographic factors (gender, education, employment) and social resources (family resources/ stressors, significant others). Findings from the majority of studies suggest that FCR remains fairly stable over time. However, most studies reporting on changes in FCR examined the concept post-treatment and over relatively short follow-up periods. Further longitudinal evidence would improve the assessment of the stability of the FCR profile over the survivorship trajectory. This review found evidence of an association between baseline FCR and later FCR, which would suggest that if FCR is initially high, it is likely to remain elevated. Actual cancer recurrence or progression was also associated with FCR [37]; however, causality cannot be inferred from these studies given the cross-sectional designs utilised.

The factor most consistently associated with FCR was younger age. Younger survivors may perceive their cancer as more unexpected [6] and report higher levels of anxiety and depression in general [48,49]. Moreover, two studies reported that survivors with young children experienced greater FCR [15,34]. Parents may be concerned about a child's emotional and behavioural adaptation to a parental diagnosis of cancer [50], and both parent and child may have significant fears about how the child would cope without the parent [51]. Survivors of cancer who have children may benefit from a family-orientated psychological intervention that accounts for the emotional concerns of both the survivor and their children [52].

The review found strong evidence for an association between physical symptoms and elevated FCR [30], as survivors may attribute unrelated symptoms to cancer recurrence. Experimental evidence suggests that somatic cues, such as the occurrence of symptoms, trigger beliefs about vulnerability and thereby elicit cancer worry [53]. Research thus far suggests that socio-demographic and disease-related factors do not contribute significantly to FCR [7]. Inconsistencies emerged regarding the role of education in FCR. Highly educated patients may have a greater understanding of the implications of a diagnosis of cancer, whereas a low level of education may impact on the information that is provided [26]. Finally, ethnicity may be important, with a growing body of research suggesting that African-American women report lower levels of FCR than Caucasian women [27].

Inconsistencies existed with regard to type of breast cancer surgery. The scarring that follows mastectomy may remind patients of their cancer [22,39], and evidence suggests that breast cancer survivors would benefit from improved information provision and management of expectations with regard to breast reconstruction [66,67]. Conversely, patients undergoing a lumpectomy may experience greater FCR than mastectomy patients as they fear the cancer has not been fully removed [54]. Conservative treatments such as endoscopic therapy for oesophageal cancer [55] and nephron-sparing surgery for renal carcinoma [38] are associated with FCR, which may relate to beliefs about whether the cancer has been fully removed.

A range of psychological factors were found to be associated with FCR. There was some evidence for an

association between FCR and other forms of psychological distress (i.e. depression) although the designs of the studies did not allow for consideration of the directionality of such relationships. In addition, there was evidence that FCR is associated with poorer mental-health-related quality of life. Further studies examining the development of FCR and its relationship to other aspects of psychological distress (i.e. depression) would contribute to the understanding of the trajectory of FCR and inform the development of interventions targeting FCR and other components of psychological distress. Such interventions to date have focussed on reducing fear of recurrence, targeting illness perceptions and inappropriate checking behaviour using a form of cognitive behavioural therapy [68] or reducing psychological distress in general among survivors using a group intervention [69].

Family factors (including family stressors and social support) [30] and gender appeared unrelated to FCR although this may reflect that few studies have examined these factors to date. The majority of studies were conducted with female cancer patients (gynaecological and breast cancers); therefore, the role of gender requires further exploration employing larger samples of mixed-gender cancer types.

The primary studies presented in this review had a range of limitations that need to be considered. The majority of the studies recruited homogenous samples in that participants were mostly White, well-educated and married. In addition, a number of the studies acknowledged the small samples sizes recruited and in some cases the low initial response rates for recruitment into the studies. Although reported response rates varied, the majority of studies reported little about non-responders. Given that more distressed individuals would be less likely to respond, then the prevalence of FCR may be underestimated in these studies. Additionally, FCR was assessed using a variety of measures, making it difficult to compare across studies. Some measures relied on a single item, which could be considered less reliable and more likely to increase the error variance in the sample. Furthermore, the measures used were not appropriate to determine if the observed levels of FCR were of clinical significance. The acquisition of such information would be useful to inform the development of interventions aimed at reducing FCR.

The designs of the studies reported in this review varied. Cross-sectional studies do not allow for changes in FCR over time to be observed and may be prone to recall bias on some of the measures used. Eleven studies utilised longitudinal designs, and although the attrition rates across time points were generally low, these designs incorporated relatively short follow-up periods. This would limit the assessment of the stability of the FCR profile over the survivorship trajectory. Furthermore, the designs utilised did not allow for the assessment of pretreatment levels of distress or the identification of factors associated with the development of FCR. Such information would help the targeting and timing of interventions to reduce FCR among cancer survivors.

The review demonstrates that FCR is a common response to a cancer diagnosis and the associated treatments. The current literature in this field does not allow one to determine the factors contributing to the development of FCR or to determine the stability of FCR over the survivorship trajectory. Further research is necessary to identify the key predictors of FCR among cancer survivors to identify at-risk groups and key factors to be targeted in an intervention. This review highlights the importance of managing the physical and emotional

consequences of cancer; however, further research is necessary to target interventions and to determine the timing of such interventions to reduce FCR among cancer survivors and support patients at risk of FCR [31]. This review provides a first step towards meeting this aim.

References

- Rowland J, Aziz N, Tesauro G, Feuer E. The changing face of cancer survivorship. *Semin Oncol Nurs* 2001;17:236–240.
- Aziz NM. Late effects of cancer treatments. In Cancer Survivorship: Today and Tomorrow, Ganz PA (ed.). Springer: New York, 2007.
- Jadoon NA, Munir W, Shahzad MA, Choudhry ZS. Assessment of depression and anxiety in adult cancer outpatients: a crosssectional study. *BMC Cancer* 2010;10:594.
- Herschbach P, Book K, Dinkel A, et al. Evaluation of two group therapies to reduce fear of progression in cancer patients. *Support Care Cancer* 2010;18:471–479.
- Simard S, Savard S, Ivers H. Fear of cancer recurrence: specific profiles and nature of intrusive thoughts. *J Cancer Surviv* 2010; 4:361–371.
- Vickberg SMJ. The Concerns About Recurrence Scales (CARS): a systematic measure of women's fears about the possibility of breast cancer recurrence. *Ann Behav Med* 2003;25:16–24.
- Llewellyn CD, Weinman J, McGurk M, Humphris G. Can we predict which head and neck cancer survivors develop fears of recurrence? J Psychosom Res 2008;65:525–532.
- Heyman EN, Rosner TT. Prostate cancer: an intimate view from patients and wives. Urol Nurs 1996;16:37–44.
- Hart SL, Latini DM, Cowan JE, *et al.* Fear of recurrence, treatment satisfaction and quality of life after radical prostatectomy for prostate cancer. *Support Care Cancer* 2008; 16:161–169.
- Black EK, White CA. Fear of recurrence, sense of coherence and posttraumatic stress disorder in haematological cancer survivors. *Psycho-Oncology* 2005;14:510–515.
- Montel S. Fear of recurrence: a case report of a woman breast cancer survivor with GAD treated successfully by CBT. *Clin Psychol Psychother* 2010;**17**:346–353.
- Van den Beuken-van Everdingen MHJ, Peters ML, de Rijke JM, Schouten HC, van Kleef M, Patign J. Concerns of former breast cancer patients about disease recurrence: a validation and prevalence study. *Psycho-Oncology* 2008;**17**:1137–1145.
- Kmet LM, Lee RC, Cook LS. Standard quality assessment criteria for evaluating primary research papers from a variety of fields. *AHFMR*, *HTA Initiative* 2004;**13**:1–21.
- Constanzo ES, Lutgendorf SK, Mattes ML, et al. Adjusting to life after treatment: distress and quality of life following treatment for breast cancer. Br J Cancer 2007;97:1625–1631.
- 15. Mehnert A, Berg P, Henrich G, Herschbach P. Fear of cancer progression and cancer related

intrusive cognitions in breast cancer patients. *Psycho-Oncology* 2009;**18**:1273–1280.

- Stanton AL, Danoff-Burg S, Huggins ME. The first year after breast cancer diagnosis: hope and coping strategies as predictors of adjustment. *Psycho-Oncology* 2002;11:93–102.
- Humphris GM, Rogers S, McNally C, Lee-Jones J, Brown D. Fear of recurrence and possible cause of anxiety and depression in orofacial cancer patients. *Int J Oral Maxillofac Surg* 2003;**32**:486–491.
- Northouse LL. Mastectomy patients and the fear of cancer recurrence. *Cancer Nurs*, 1981;4:213–220.
- Mehta SS, Lubeck DP, Pasta DJ, Litwin MS. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. J Urol 2003; 170:1931–1933.
- Hodges L, Humphris GM. Fear of recurrence and psychological distress in head and neck cancer patients and their carers. *Psycho-Oncology* 2009;18:841–848.
- Bellizi KM, Latini DM, Cowan JE, DuChane J, Carroll PR. Fear of recurrence, symptom burden and health related quality of life in men with prostate cancer. *Urology* 2009; 72:1269–1273.
- 22. Curran D, van Dongen JP, Aaronson NK, et al. Quality of life of early stage breast cancer patients treated with radical mastectomy or breast conserving procedures: results of EORTC trial 10801. Eur J Cancer 1998;24:307–314.
- De Haes JCJM, Welvaart K. Quality of life after breast cancer surgery. J Surg Oncol 1985;28:123–125.
- Kornblith AB, Powell M, Regen MM, et al. Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. *Psycho-Oncology* 2007;16:895–903.
- Härtl K, Janni W, Kästner R, *et al.* Impact of medical and demographic factors on long term quality of life and body image of breast cancer patients. *Ann Oncol* 2003;14:1064–1071.
- 26. Janz N, Hawley S, Mujahid MS, et al. Correlates of worry about recurrence in a multiethnic population based sample of women with breast cancer. American Cancer Society 2011;117:1827–1836.
- McGinty HL, Goldenberg JL, Jacobsen PB. Relationship of threat appraisal with coping appraisal to fear of cancer recurrence in breast cancer survivors. *Psycho-Oncology* 2012; 21:203–210.
- Leake RL, Gurrin LC, Hammond IG. Quality of life in patients attending a low risk gynaecological oncology follow-up clinic. *Psycho-Oncology* 2001;10:428–435.
- Skaali T, Fossa SD, Bremnes R, et al. Fear of recurrence in long term testicular cancer survivors. Psycho-Oncology 2009;18:580–588.

- Mellon S, Kershaw TS, Northouse LL, Freeman-Gibb L. A family-based model to predict fear of recurrence for cancer survivors and their caregivers. *Psycho-Oncology* 2007; 16:214–223.
- Gill KM, Mishel MH, Belyea M, et al. Triggers of uncertainty about recurrence and long-term treatment effects in older African American and Caucasian breast cancer survivors. Oncol Nurs Forum 2004;31:633–639.
- Deimling GT, Bowman K, Sterns S, Wagner LJ, Kahana B. Cancer related health worries and psychological distress among older adult long term cancer survivors. *Psycho-Oncology* 2006;15:306–320.
- Bergman J, Gore JL, Seigal CS, Kwan L, Litwin MS. Partnership and outcomes in men with prostate cancer. *Cancer* 2009; 115:4688–4694.
- 34. Steele N, Haigh R, Knowles G, Mackean M. Carcinoembryonic antigen testing in colorectal cancer follow up: what do patients think? *Postgrad Med* 2007;83:612–614.
- Rogers SN, Scott B, Lowe D, Ozakinci G, Humphris GM. Fear of recurrence following head and neck cancer in the outpatient clinic. *Eur Arch Otorhinolaryngol* 2010;267:1943–1949.
- Rabin C, Leventhal H, Goodin S. Conceptualisation of disease timeline predicts posttreatment distress in breast cancer patients. *Health Psychol* 2004;23:407–412.
- Shim EJ, Shin Y, Oh DY, Hahm B. Increased fear of progression in cancer patients with recurrence. *Gen Hosp Psychiatry* 2010; 32:169–175.
- Poulakis V, Witzch U, de Vries R, Moeckel M, Becht E. Quality of life after surgery for localised renal cell carcinoma: comparison between radical nephrectomy and nephron sparing surgery. *Urology* 2003;62:814–820.
- Lasry JCM, Margolese RG. Fear of recurrence, breast-conserving surgery, and the trade off hypothesis. *Cancer* 1992;69:2111–2115.
- Lasry JCM, Margolese RG, Poisson R, et al. Depression and body image following mastectomy and lumpectomy. J Chron Dis 1987;40:529–534.
- De Haes JCJM, van Oostrum MA, Welvaart K. The effect of radical and conserving surgery on the quality of life of early breast cancer patients. *Eur J Surgical Oncology* 1986;12:337–342.
- 42. Noguchi M, Kitagawa H, Kinoshita K, et al. Psychologic and cosmetic self-assessments of breast conserving therapy compared with mastectomy and immediate breast reconstruction. J Surg Oncol 1993;54:260–266.
- 43. De Haes JCJM, Curran D, Aaronson NK, Fentiman IS. Quality of life in breast cancer patients aged over 70 years, participating in the EORTC 10850 randomised clinical trial. *Eur J Cancer* 2003;**39**:945–951.

Fear of recurrence

- 44. Bartelink H, van Dam F, van Dongen J. Psychological effects of breast conserving therapy in comparison with radical mastectomy. *Int J Radiation Oncology Biol Phys* 1985:11:381–385.
- Kemeny MM, Wellisch DK, Schain WS. Psychosocial outcome in a randomised surgical trial for treatment of primary breast cancer. *Cancer* 1998;62:1231–1237.
- 46. Rosmolen WD, Boer KR, de Leeuw RJR, et al. Quality of life and fear of cancer recurrence after endoscopic and surgical treatment for early neoplasia in Barrett's esophagus. Endoscopy 2010;42:525–531.
- Wade TD, Nehmy T, Koczwara B. Predicting worries about health after breast cancer surgery. *Psychooncology* 2005;14:503–509.
- Hipkins J, Whitworth M, Tarrier N, Jayson G. Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study. Br J Health Psychol 2004;9:569–581.
- Arden-Close E, Gidron Y, Moss-Morris R. Psychological distress and its correlates in ovarian cancer: a systematic review. *Psycho-Oncology* 2008;17:1061–1072.
- Visser A, Huizinga GA, Hoekstra HJ, et al. Emotional and behavioral problems in children of parents recently diagnosed with cancer: a longitudinal study. Acta Oncol 2007;46:67–76.
- Osborn T. The psychosocial impact of parental cancer on children and adolescents: a systematic review. *Psycho-Oncology* 2007; 16:101–126.
- 52. Thastum M, Watson M, Kienbacher C, *et al.* Prevalence and predictors of emotional and behavioural functioning of children where a

parent has cancer: a multinational study. *Cancer* 2009;**115**:4030–4039.

- Easterling D, Leventhal H. Contribution of concrete cognition to emotion: neutral symptoms as elicitors of worry about cancer. *J Appl Psychol* 1989;**74**:787–796.
- Fallowfield LJ, Baum M, Maguire GP. Effects of breast conservation on psychological morbidity associated with diagnosis and treatment of early breast cancer. *Br Med J* 1986:293:1331–1334.
- 55. Humprhis GM, Roger SN. The association of cigarette smoking and anxiety, depression and fears of recurrence in patients following treatment of oral and oropharyngeal malignancy. *Eur J Cancer Care* 2004;**13**:328–335.
- Simard S, Savard J. Fear of cancer recurrence inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. *Support Care Cancer* 2009;17:241–251.
- Burnstein HJ, Glebbr S, Guadagoli E, Weeks J. Use of alternative medicine by women with early-stage breast cancer. *N Engl J Med* 1999;**340**:1733–1739.
- Meyerowitz BE. Psychological correlations of breast cancer and its treatments. *Psychol Bull* 1980;87:108–131.
- Wellisch DK, Schain WS, Noone BR, Little JW. Psychosocial correlates of immediate versus delayed reconstruction of the breast. *Plast Reconstr Surg* 1985;**76**:713–718.
- 60. Avery AD, Lelak T, Solomon NE, et al. Quality of Medical Care Assessment Using Outcome Measures. Eight Disease Specific Applications. Rand: Santa Monica, 1986.
- 61. Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer

patients: the Functional Living Index—cancer. *J Clin Oncol* 1984;**2**:472–483.

- Greenberg DB, Kornblith AB, Herndon JE, et al. Quality of life of adult leukemia survivors treated on clinical trials of the Cancer and Leukemia Group. Cancer 1997;80:1936–1944.
- Bowman KF, Smerglia VL, Deimling GT. A stress model of cancer survivorship in older long-term survivors. J Ment Health Aging 2004;10:163–182.
- Roth AJ, Rosenfeld B, Kornblith AB, *et al.* The Memorial Anxiety Scale for prostate cancer. *Cancer* 2003;97:2910–2918.
- 65. Mehnert A, Herschbach P, Petra B, et al. Fear of progression in breast cancer patients validation of the short form of the Fear of Progression Questionnaire. Zeitschrift für Psychoso Med Psycho 2006;52:274–288.
- 66. Abu-Nab Z, Grunfeld EA. Satisfaction with outcome and attitudes towards scarring among women undergoing breast reconstructive surgery. *Patient Educ Couns* 2007;66 (2):243–249.
- Begum S, Grunfeld EA, Ho-Asjoe M, Farhadi J. An exploration of patient decision-making for autologous breast reconstructive surgery following a mastectomy. *Patient Educ Couns* 2011;84(1):105–110.
- Humphris G, Ozakinci G. The AFTER intervention: a structured psychological approach to reduce fears of recurrence in patients with head and neck cancer. *Br J Health Psychol* 2008;13:223–230.
- Fukui S, Kugaya A, Okamura H, *et al.* A psychosocial group intervention for Japanese women with primary breast carcinoma. *Cancer* 2000;**89**:1026–1036.